Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,690 matching trials from the live ClinicalTrials.gov search.
Conditions
Moderate to Severe Glabellar Lines
Interventions
Corabotase, Placebo
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 13 more
Conditions
Solid Tumors
Interventions
AV-203
Biological
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Scottsdale, Arizona • Atlanta, Georgia • San Antonio, Texas
Terminated Phase 2Phase 3 Interventional Results available

SPARK-ALL: Calaspargase Pegol in Adults With ALL

NCT04817761
Conditions
Acute Lymphoblastic Leukemia
Interventions
Calaspargase pegol (S95015)
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
22 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more
Conditions
Cancer, Neoplasm Metastasis
Interventions
TRC105 chimeric anti-CD105 antibody
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Scottsdale, Arizona • Santa Monica, California • Buffalo, New York + 1 more
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions
regorafenib, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 1 more
Conditions
Obesity
Interventions
vBloc (Active Device), Sham (Non-active Device)
Device
Lead sponsor
ReShape Lifesciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • La Jolla, California • Stanford, California + 5 more
Conditions
X-Linked Retinitis Pigmentosa
Interventions
rAAV2tYF-GRK1-hRPGRco, Control
Biological · Drug
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
12 Years to 50 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 15 more
Conditions
Major Depressive Disorder
Interventions
Quetiapine fumarate, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 31 more
Conditions
Obesity, Overweight
Interventions
Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
43
States / cities
Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more
Conditions
Advanced or Metastatic NSCLC
Interventions
Datopotamab deruxtecan, KEYTRUDA®, Carboplatin, Cisplatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more
Conditions
Plantar Fibromatosis, Ledderhose Disease
Interventions
EN3835, Placebo
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
63
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 55 more
Conditions
Colonic Diseases
Interventions
PillCam Colon capsule endoscopy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Scottsdale, Arizona • Indianapolis, Indiana • Minneapolis, Minnesota + 3 more
Conditions
Metastatic Breast Cancer
Interventions
Paclitaxel+Reparixin
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Scottsdale, Arizona • Fairway, Kansas • Ann Arbor, Michigan + 1 more
Conditions
Congestive Heart Failure, Cardiac Resynchronization Therapy
Interventions
Kronos LV-T, Lumax HF-T
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Wilmington, Delaware + 9 more
Conditions
Down Syndrome, Edwards Syndrome, Patau Syndrome, Klinefelter Syndrome, Turner Syndrome, DiGeorge Syndrome, Chromosome Deletion, Aneuploidy
Interventions
Blood sampling for Laboratory Developed Test (LDT) analysis
Other
Lead sponsor
Progenity, Inc.
Industry
Eligibility
18 Years to 54 Years · Female only
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Scottsdale, Arizona • Eunice, Louisiana • Brooklyn, New York + 5 more
Conditions
Hidradenitis Suppurativa
Interventions
SAR445399, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • North Hollywood, California • Boynton Beach, Florida + 16 more
Conditions
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelofibrosis, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Erdheim-Chester Disease, Refractory Follicular Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoplasmacytic Lymphoma, Refractory Myelodysplastic Syndrome, Refractory Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Refractory Waldenstrom Macroglobulinemia, Rosai-Dorfman-Destombes Disease, Primary Central Nervous System Lymphoma, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Erdheim-Chester Disease, Recurrent Fibroblastic Reticular Cell Sarcoma, Recurrent Histiocytic Sarcoma, Recurrent Interdigitating Dendritic Cell Sarcoma, Recurrent Rosai-Dorfman-Destombes Disease, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Fibroblastic Reticular Cell Sarcoma, Refractory Histiocytic Sarcoma, Refractory Interdigitating Dendritic Cell Sarcoma, Refractory Rosai-Dorfman-Destombes Disease
Interventions
Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
227
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Lenalidomide, Dexamethasone, Anticoagulants
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, azelastineHcl, fluticasone propionate, azelastine Hcl/fluticasone propionate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,791 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
45
States / cities
Scottsdale, Arizona • Encinitas, California • Fountain Valley, California + 35 more
Conditions
Sarcopenia, Debility Due to Disease
Interventions
exercise, placebo
Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Myeloid Malignancy, Inherited Bone Marrow Failure Syndrome, Clonal Expansion, Cytopenia, Bone Marrow Failure Syndrome, Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis of Indeterminate Potential, Hematologic Neoplasms, Hematopoietic and Lymphatic System Neoplasm, Hereditary Neoplastic Syndrome, Idiopathic Cytopenia of Undetermined Significance, Idiopathic Dysplasia of Uncertain Significance, Low Risk Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Punch Biopsy, Buccal Swab, Clinical Evaluation, Genetic Counseling, Quality-of-Life Assessment, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Lymphedema, Stage IA Cervical Cancer, Stage IA Uterine Corpus Cancer, Stage IA Vulvar Cancer, Stage IB Cervical Cancer, Stage IB Uterine Corpus Cancer, Stage IB Vulvar Cancer, Stage II Uterine Corpus Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Vulvar Cancer, Stage IVB Vulvar Cancer
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Study of High Risk Factors, Therapeutic Conventional Surgery, Therapeutic Laparoscopic Surgery, Therapeutic Lymphadenectomy
Other · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
1,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
213
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
Conditions
Melanoma, Cutaneous Malignant
Interventions
IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel
Biological · Drug
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more